Damon Wang

Company: Nucyrna Therapeutics

Job title: CEO

Seminars:

Roundtable Discussion: Advancing Dose Selection & Translational PK/PD Modeling for Oligonucleotide Therapeutics & Brain Shuttles in the CNS 1:30 pm

Leverage translational PK/PD modeling to inform dose selection and understand exposure-response relationships in the CNS for oligonucleotide-based therapies Explore brain shuttle and Transferrin Receptor mediated uptake and modeling strategies to assess CNS exposure and PK ‘hit’ Integrate intrathecal distribution data into predictive frameworks to optimize therapeutic delivery and biodistribution Case examples and lessons learned from…Read more

day: Day 2

Roundtable Discussion: Demonstrating Reduced Chronic Oligonucleotide Toxicity Across Both Rodents & NHP Models 11:30 am

Accumulate chronic toxicity data in NHPs to understand common threads in toxicities and understand the pathology underlying chronic toxicity Build cutting edge rodent models that can recapitulate chronic oligonucleotide toxicity by reverse translating observations in NHPs, overcoming the disconnect in toxicity observations between NHPs and rodent systems with oligonucleotides Integrate models into clinical practice to…Read more

day: Day 2